» Articles » PMID: 20056635

Marginal and Mixed-effects Models in the Analysis of Human Papillomavirus Natural History Data

Abstract

Human papillomavirus (HPV) natural history has several characteristics that, at least from a statistical perspective, are not often encountered elsewhere in infectious disease and cancer research. There are, for example, multiple HPV types, and infection by each HPV type may be considered separate events. Although concurrent infections are common, the prevalence, incidence, and duration/persistence of each individual HPV can be separately measured. However, repeated measures involving the same subject tend to be correlated. The probability of detecting any given HPV type, for example, is greater among individuals who are currently positive for at least one other HPV type. Serial testing for HPV over time represents a second form of repeated measures. Statistical inferences that fail to take these correlations into account would be invalid. However, methods that do not use all the data would be inefficient. Marginal and mixed-effects models can address these issues but are not frequently used in HPV research. The current study provides an overview of these methods and then uses HPV data from a cohort of HIV-positive women to illustrate how they may be applied, and compare their results. The findings show the greater efficiency of these models compared with standard logistic regression and Cox models. Because mixed-effects models estimate subject-specific associations, they sometimes gave much higher effect estimates than marginal models, which estimate population-averaged associations. Overall, the results show that marginal and mixed-effects models are efficient for studying HPV natural history, but also highlight the importance of understanding how these models differ.

Citing Articles

Human Papillomavirus, Human Immunodeficiency Virus, and Oral Microbiota Interplay in Nigerian Youth (HOMINY): A Prospective Cohort Study Protocol.

Osagie E, Akhigbe P, Idemudia N, Obuekwe O, Adebiyi R, Schlecht N BMJ Open. 2025; 15(2):e091017.

PMID: 39922591 PMC: 11808902. DOI: 10.1136/bmjopen-2024-091017.


Changes in Genital Human Papillomavirus (HPV) Prevalence During 12 Years of Girls-Only Bivalent HPV Vaccination: Results From a Biennial Repeated Cross-sectional Study.

Kusters J, Schim van der Loeff M, Heijne J, King A, de Melker H, Heijman T J Infect Dis. 2024; 231(1):e165-e176.

PMID: 39271142 PMC: 11793022. DOI: 10.1093/infdis/jiae455.


Zipime-Weka-Schista study protocol: a longitudinal cohort study and economic evaluation of an integrated home-based approach for genital multipathogen screening in women, including female genital schistosomiasis, human papillomavirus, Trichomonas....

Shanaube K, Ndubani R, Kelly H, Webb E, Mayaud P, Lamberti O BMJ Open. 2024; 14(6):e080395.

PMID: 38858160 PMC: 11168163. DOI: 10.1136/bmjopen-2023-080395.


Detection and Clearance of Type-Specific and Phylogenetically Related Genital Human Papillomavirus Infections in Young Women in New Heterosexual Relationships.

Arthur A, El-Zein M, Burchell A, Tellier P, Coutlee F, Franco E J Infect Dis. 2023; 229(3):691-706.

PMID: 37824429 PMC: 10938200. DOI: 10.1093/infdis/jiad450.


A novel human papillomavirus and host DNA methylation score and detection of cervical adenocarcinoma.

Gradissimo A, Clarke M, Xue X, Castle P, Raine-Bennett T, Schiffman M J Natl Cancer Inst. 2023; 115(12):1535-1543.

PMID: 37467068 PMC: 10699843. DOI: 10.1093/jnci/djad134.


References
1.
Rodriguez A, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle P . Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008; 100(7):513-7. PMC: 3705579. DOI: 10.1093/jnci/djn044. View

2.
. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2008; 90:1-636. PMC: 4781057. View

3.
Wacholder S . Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986; 123(1):174-84. DOI: 10.1093/oxfordjournals.aje.a114212. View

4.
McNutt L, Wu C, Xue X, Hafner J . Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157(10):940-3. DOI: 10.1093/aje/kwg074. View

5.
Xie T, Waksman J . Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint. Stat Med. 2003; 22(18):2835-46. DOI: 10.1002/sim.1536. View